Compositions and methods for treatment of lung disorders characterized by cholesterol dysregulation
AssigneeChildren's Hospital Medical Center
InventorsBruce Trapnell, Tony Sallese, Brenna Carey, Takuji Suzuki
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPARγ agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.
Claims15
A method of treating a condition characterized by a dysregulation in macrophage lipid homeostasis, comprising the step of administering an agent selected from a PPARγ agonist, a LXR agonist, or a combination thereof.
A method of decreasing lung infection in an individual having PAP comprising the step of administering an agent selected from a PPARγ agonist, a LXR agonist, and a combination thereof.
An article of manufacture comprising a container, a composition comprising a unit dose of a PPARγ agonist, a LXR agonist, or a combination thereof, and instructions for administering said dose to an individual diagnosed or suspected of having PAP or a symptom associated with PAP.
Dependencies are inferred from the claim text.